Compass Group PLC CMPGY
33.98 USD +0.34 (+1.01%)
At closeNov 11, 2026, 4:00 PM EST
33.19 Day range 34.01
26.95 52-week range 34.81
- YTD
- +6.22%
- 1 year
- +1.89%
News
globenewswire.com Deadline Alert: Compass, Inc. Investors Have Until December 8, 2026 to Seek Lead Plaintiff Role in Securities Fraud Class Action, Glancy Prongay Wolke & Rotter LLP Reminds Investors Class action covers investors who bought Compass, Inc. securities between January 9, 2026 and October 7, 2026; complaint alleges the company failed to disclose material adverse facts Class action…
prnewswire.com COMP Shareholder Alert: Compass, Inc. Securities Class Action Lawsuit - Investors Should Contact Levi & Korsinsky Key Dates and Disclosure Events Shareholders Need to Know: Compass's merger timeline pointed to a second-half 2026 close, but the lawsuit alleges an undisclosed DOJ backchannel, not ordinary…
businesswire.com Compass Pathways to Participate in Jefferies Global Healthcare Conference on November 18th and 19th LONDON & JERSEY CITY, N.J.--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental…
globenewswire.com INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Compass, Inc. of Class Action Lawsuit and Upcoming Deadlines – COMP NEW YORK, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Compass, Inc. (“Compass” or the “Company”) (NYSE: COMP). Such investors are…
globenewswire.com COMPASS INVESTOR ALERT: Bragar Eagel & Squire, P.C. Reminds Compass, Inc. Investors They Have Until December 7th to Contact the Firm Seeking Lead Plaintiff Role Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Compass (COMP) To Contact Him Directly To Discuss Their Options
globenewswire.com COMP DEADLINE: SueWallSt Reminds Compass, Inc. Investors of Upcoming Securities Class Action Deadline From Optimism to Disillusionment: Confidence in Compass's $4.2 billion Anywhere merger gave way to three waves of selling, and the lawsuit claims the Offering Materials never disclosed an alleged…
prnewswire.com What's Next for Compass, Inc. Shareholders After 28% Stock Drop? Glancy Prongay Wolke & Rotter LLP Explains Securities Fraud Class Action Lead Plaintiff Deadline Complaint alleges Compass, Inc. misled investors between January 9, 2026 and October 7, 2026; investors may seek lead plaintiff role by December 8, 2026 LOS ANGELES, Nov. 9, 2026 /PRNewswire/ --…
newsfilecorp.com Bronstein, Gewirtz & Grossman LLC Urges Compass, Inc. Investors to Act: Class Action Filed Alleging Investor Harm New York, New York--(Newsfile Corp. - November 9, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed on…
prnewswire.com Compass, Inc. (COMP) Investors Have Opportunity to Lead Securities Fraud Class Action Lawsuit - Kessler Topaz Meltzer & Check, LLP Are you a former Anywhere Real Estate Inc. shareholder who exchanged your shares of Anywhere stock for Compass, Inc. common stock in connection with the January 2026 merger? Affected COMP Investor…
globenewswire.com COMP Shareholder Alert: Compass, Inc. Securities Class Action Lawsuit - Investors With Losses May Contact Levi & Korsinsky Former Anywhere shareholders who received Compass stock in the January 2026 merger exchange are urged to review their options. Securities Act claims allege the S-4 registration statement omitted a…
prnewswire.com COMP Stock Drop - Robbins LLP Reminds Investors They May Be Eligible to Lead the Class Action Lawsuit Against Compass, Inc. SAN DIEGO, Nov. 9, 2026 /PRNewswire/ -- Shareholder rights law firm Robbins LLP reminds investors that a class action was filed on behalf of former Anywhere Real Estate Inc. ("Anywhere") (formerly…
globenewswire.com Compass Therapeutics Reports 2026 Third Quarter Financial Results and Provides Corporate Update Compass is advancing preparations for a BLA submission for tovecimig in patients with BTC and plans to further engage with the FDA. Data from the COMPANION-002 study of tovecimig, including newly…
businesswire.com Compass Pathways Completes COMP360 Psilocybin New Drug Application to U.S. FDA for Treatment-Resistant Depression LONDON & JERSEY CITY, N.J.--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental…
marketbeat.com Compass Q3 Earnings Call Highlights Compass NYSE: COMP reported record third-quarter revenue and profit as cost cuts following its Anywhere acquisition helped offset a difficult housing market, but executives warned that weaker pending…
seekingalpha.com Compass, Inc. (COMP) Q3 2026 Earnings Call Transcript Compass, Inc. ( COMP ) Q3 2026 Earnings Call November 5, 2026 5:00 PM EST Company Participants Soham Bhonsle - Head of Investor Relations Robert Reffkin - Founder, Chairman & CEO Scott Wahlers - CFO…
globenewswire.com Bronstein, Gewirtz & Grossman LLC Urges Compass, Inc. Investors to Act: Class Action Filed Alleging Investor Harm New class action for Compass, Inc. (COMP) urges investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of 12/7/2026
seekingalpha.com Compass: Lofty Market Share Gains As The Company Tightens Its Grip On The Industry Compass offers a compelling diversification play as investors rotate from AI stocks to real economy names. Despite strong Q3 results and industry outperformance, COMP shares are down ~20% since…
globenewswire.com Compass Therapeutics Presents Novel Mechanism of Action Data for CTX-10726 (PD-1 x VEGF-A Bispecific Antibody) at the SITC 2026 Annual Meeting CTX-10726, a PD-1 x VEGF-A bispecific antibody discovered and engineered at Compass, exhibits a unique mechanism of action that has not been previously reported in this class of drugs, characterized…
prnewswire.com INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Compass, Inc. of Class Action Lawsuit and Upcoming Deadlines - COMP NEW YORK, Nov. 5, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Compass, Inc. ("Compass" or the "Company") (NYSE: COMP). Such investors are advised…
zacks.com Compass, Inc. (COMP) Meets Q3 Earnings Estimates Compass, Inc. (COMP) came out with quarterly earnings of $0.07 per share, in line with the Zacks Consensus Estimate . This compares to a loss of $0.01 per share a year ago.
businesswire.com Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) LONDON & JERSEY CITY, N.J.--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental…
prnewswire.com Compass, Inc. Reports Record Third Quarter 2026 Results All-time Q3 Records for Revenue, Net Income, Adjusted EBITDA and Operating Cash Flow Q3 Reven ue +12% YoY1; GAAP Net Income $62 Million; Adjusted EBITDA2 $306 Million Operating Cash Flow $248…
prnewswire.com What Should Compass, Inc. Investors Know After 28% Stock Drop? The Law Offices of Frank R. Lawsuit alleges Compass, Inc. made misleading statements to investors from January 9, 2026 to October 7, 2026; lead plaintiff motions are due December 8, 2026 LOS ANGELES, Nov. 5, 2026 /PRNewswire/…